From: Cell therapies for chondral defects of the talus: a systematic review
Author, year | Journal | Study Design | Follow-up (months) | Treatment | Procedures (n) | Female (%) | Mean age | Mean BMI | Mean defect size (cm2) |
---|---|---|---|---|---|---|---|---|---|
Buda et al. [51] | Int Orthop | Retrospective | 48.0 | Control group (mACI) | 40 | 37.5 | 31.4 | Â | 1.7 |
BMAC | 40 | 32.5 | 30.2 | Â | 1.8 | ||||
Desando et al. [52] | Cartilage | Prospective | 36.0 | Control group (mACI) | 7 | 42.9 | 31.2 | Â | 1.8 |
36.0 | BMAC | 15 | 33.3 | 31.0 | Â | ||||
Guney et al. [53] | Knee Surg Sports Traumatol Arthrosc | Prospective | 47.3 | Control group (MFX) | 19 | 37.4 | 47, 4 | Â | Â |
40.4 | MFX & PRP | 22 | 43.9 | 50.0 | Â | Â | |||
30.1 | Control group (Mosaicplasty) | 13 | 37.6 | 15.4 |  |  > 0.2 | |||
Murphy et al. [54] | Knee Surg Sports Traumatol Arthrosc | Retrospective | 36.7 | MAST | 38 | 31.2 | 35.0 | Â | 1.7 |
Nguyen et al. [55] | Am J Sports Med | Retrospective | 44.7 | OAT & BMA, or PRGF | 38 | 0.0 | 26.0 | Â | 2.5 |
Richter et al. [56] | Foot Ankle Surg | Prospective | 24.0 | MAST & BMC | 26 | 28.0 | 33.0 | Â | 1.1 |
Richter et al. [57] | Foot Ankle Surg | Prospective | 24.4 | MAST & BMC | 129 | 41.0 | 35.3 | Â | 1.6 |
23.8 | AMIC & PBC | 129 | 40.0 | 35.6 | Â | 1.8 |